PMID- 24150413 OWN - NLM STAT- MEDLINE DCOM- 20131223 LR - 20240321 IS - 1476-4660 (Electronic) IS - 1476-1122 (Print) IS - 1476-1122 (Linking) VI - 12 IP - 11 DP - 2013 Nov TI - Strategies for advancing cancer nanomedicine. PG - 958-62 LID - 10.1038/nmat3792 [doi] AB - Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by physiological barriers posed by the tumour microenvironment. Here, we discuss how these barriers can be overcome through innovative nanomedicine design and through creative manipulation of the tumour microenvironment. FAU - Chauhan, Vikash P AU - Chauhan VP AD - 1] Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA [2] Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. FAU - Jain, Rakesh K AU - Jain RK LA - eng GR - T32 CA073479/CA/NCI NIH HHS/United States GR - R01 CA126642/CA/NCI NIH HHS/United States GR - R01 CA163815/CA/NCI NIH HHS/United States GR - P01-CA080124/CA/NCI NIH HHS/United States GR - T32-CA073479/CA/NCI NIH HHS/United States GR - R01-CA163815/CA/NCI NIH HHS/United States GR - P01 CA080124/CA/NCI NIH HHS/United States GR - R01-CA126642/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PL - England TA - Nat Mater JT - Nature materials JID - 101155473 SB - IM MH - Animals MH - Humans MH - Nanomedicine/*methods MH - Neoplasms/drug therapy/pathology/*therapy MH - Tumor Microenvironment/drug effects PMC - PMC4120281 MID - NIHMS594118 EDAT- 2013/10/24 06:00 MHDA- 2013/12/24 06:00 PMCR- 2014/11/01 CRDT- 2013/10/24 06:00 PHST- 2013/10/24 06:00 [entrez] PHST- 2013/10/24 06:00 [pubmed] PHST- 2013/12/24 06:00 [medline] PHST- 2014/11/01 00:00 [pmc-release] AID - nmat3792 [pii] AID - 10.1038/nmat3792 [doi] PST - ppublish SO - Nat Mater. 2013 Nov;12(11):958-62. doi: 10.1038/nmat3792.